Wealthspire Advisors LLC Decreases Position in Regeneron Pharmaceuticals, Inc. $REGN

Wealthspire Advisors LLC decreased its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 34.4% in the second quarter, Holdings Channel reports. The firm owned 6,137 shares of the biopharmaceutical company’s stock after selling 3,213 shares during the period. Wealthspire Advisors LLC’s holdings in Regeneron Pharmaceuticals were worth $3,222,000 as of its most recent SEC filing.

Several other hedge funds also recently added to or reduced their stakes in the business. Activest Wealth Management boosted its holdings in Regeneron Pharmaceuticals by 110.5% in the first quarter. Activest Wealth Management now owns 40 shares of the biopharmaceutical company’s stock worth $25,000 after acquiring an additional 21 shares in the last quarter. Costello Asset Management INC acquired a new position in shares of Regeneron Pharmaceuticals during the first quarter valued at about $27,000. Saudi Central Bank purchased a new position in shares of Regeneron Pharmaceuticals in the 1st quarter valued at approximately $27,000. Migdal Insurance & Financial Holdings Ltd. acquired a new stake in Regeneron Pharmaceuticals in the 2nd quarter worth approximately $31,000. Finally, Colonial Trust Advisors acquired a new stake in Regeneron Pharmaceuticals in the 1st quarter worth approximately $32,000. 83.31% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Regeneron Pharmaceuticals

In other Regeneron Pharmaceuticals news, VP Jason Pitofsky sold 431 shares of Regeneron Pharmaceuticals stock in a transaction on Friday, November 7th. The shares were sold at an average price of $651.43, for a total transaction of $280,766.33. Following the sale, the vice president owned 4,233 shares of the company’s stock, valued at $2,757,503.19. The trade was a 9.24% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Christine A. Poon sold 6,500 shares of the stock in a transaction dated Wednesday, October 29th. The shares were sold at an average price of $654.27, for a total transaction of $4,252,755.00. Following the completion of the sale, the director owned 2,352 shares of the company’s stock, valued at $1,538,843.04. This trade represents a 73.43% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders own 7.02% of the company’s stock.

Analyst Ratings Changes

A number of research analysts have issued reports on REGN shares. Royal Bank Of Canada raised their price target on shares of Regeneron Pharmaceuticals from $704.00 to $708.00 and gave the stock a “sector perform” rating in a report on Wednesday, October 29th. Canaccord Genuity Group restated a “buy” rating and issued a $850.00 target price on shares of Regeneron Pharmaceuticals in a research note on Thursday, October 23rd. Wells Fargo & Company boosted their price target on Regeneron Pharmaceuticals from $580.00 to $615.00 and gave the company an “equal weight” rating in a research note on Wednesday, October 29th. Redburn Atlantic upgraded Regeneron Pharmaceuticals to a “strong-buy” rating in a research note on Thursday, August 14th. Finally, Jefferies Financial Group lifted their target price on Regeneron Pharmaceuticals from $813.00 to $831.00 and gave the stock a “buy” rating in a report on Wednesday, August 27th. Two equities research analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating, eight have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $772.76.

Regeneron Pharmaceuticals Stock Performance

REGN opened at $702.75 on Thursday. The firm has a fifty day moving average price of $608.00 and a 200 day moving average price of $573.41. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.06 and a quick ratio of 3.72. Regeneron Pharmaceuticals, Inc. has a 1 year low of $476.49 and a 1 year high of $800.99. The stock has a market cap of $73.86 billion, a P/E ratio of 16.83, a P/E/G ratio of 2.03 and a beta of 0.31.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings results on Tuesday, October 28th. The biopharmaceutical company reported $11.83 earnings per share for the quarter, beating the consensus estimate of $9.73 by $2.10. Regeneron Pharmaceuticals had a return on equity of 13.76% and a net margin of 32.13%.The firm had revenue of $3.75 billion during the quarter, compared to analyst estimates of $3.57 billion. During the same quarter in the previous year, the business earned $12.46 EPS. Regeneron Pharmaceuticals’s revenue for the quarter was up .9% compared to the same quarter last year. Equities research analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current year.

Regeneron Pharmaceuticals Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, December 5th. Stockholders of record on Thursday, November 20th will be given a $0.88 dividend. This represents a $3.52 annualized dividend and a dividend yield of 0.5%. The ex-dividend date is Thursday, November 20th. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is 8.43%.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.